[Pubmed] The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder
Posté : 07 janv. 2023 12:00
Curr Atheroscler Rep. 2023 Jan 7. doi: 10.1007/s11883-022-01077-9. Online ahead of print.
ABSTRACT
PURPOSE OF REVIEW: We describe and discuss the safety of statins and non-statin drugs in neuromuscular disorders (NMDs). We also propose a pragmatic model of care for the management of such cases.
RECENT FINDINGS: Patients with both NMD and hypercholesterolemia may be particularly disadvantaged owing to the toxic effects of cholesterol-lowering therapy and the inability to take medication. Specifically, the management of hypercholesterolemia in patients with NMD is complicated by the increased risk of statin-related myotoxicity and concerns that statins may aggravate or possibly induce the onset of a specific NMD. The most severe form of statin-related myotoxicity is immune-mediated necrotizing myopathy. Management of hypercholesterolemia in patients with NMDs include treating modifiable factors, consideration of toxicity risk of statin, use of non-statin lipid lowering agents, noting possible drug interactions, and careful monitoring.
PMID:36609642 | DOI:10.1007/s11883-022-01077-9
Source: https://pubmed.ncbi.nlm.nih.gov/3660964 ... t6+86293ac